Annie Xiaoyu An, Lily Tong, Davy Ouyang, Dan Duan, Jinping Liu, Tingting Li, Lei Liu, Ling Xu, Ying Jin, Wenqing Yang, Xin Dong*, Jay Liu*, and Henry Q.X. Li
*Nanjing Galaxy Biopharmaceutical Co. Ltd., Nanjing
Immunotherapies such as checkpoint inhibitors have achieved great success in treating cancer patients clinically. However, not all patients respond to these agents, most likely due to patients’ and/or tumors’ genetic and immunological makeup, particularly of the tumor microenvironment (TME).
The connections between specific immune compartments of the TME with response to immunotherapy remain to be elucidated, and preclinical animal models could potentially be highly useful for this research.
CrownBio has developed various novel immuno-oncology models and this poster covers the investigation into model TME, and its relationship with immunotherapy treatment outcomes.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-05-22
2021-10-28
landing_page
PDX/Databases